000152040 001__ 152040
000152040 005__ 20250326144154.0
000152040 0247_ $$2doi$$a10.3389/fimmu.2021.730710
000152040 0248_ $$2sideral$$a126386
000152040 037__ $$aART-2021-126386
000152040 041__ $$aeng
000152040 100__ $$aVillar, M.
000152040 245__ $$aCharacterization by Quantitative Serum Proteomics of Immune-Related Prognostic Biomarkers for COVID-19 Symptomatology
000152040 260__ $$c2021
000152040 5060_ $$aAccess copy available to the general public$$fUnrestricted
000152040 5203_ $$aThe COVID-19 pandemic caused by SARS-CoV-2 challenges the understanding of factors affecting disease progression and severity. The identification of prognostic biomarkers and physiological processes associated with disease symptoms is relevant for the development of new diagnostic and therapeutic interventions to contribute to the control of this pandemic. To address this challenge, in this study, we used a quantitative proteomics together with multiple data analysis algorithms to characterize serum protein profiles in five cohorts from healthy to SARS-CoV-2-infected recovered (hospital discharge), nonsevere (hospitalized), and severe [at the intensive care unit (ICU)] cases with increasing systemic inflammation in comparison with healthy individuals sampled prior to the COVID-19 pandemic. The results showed significantly dysregulated proteins and associated biological processes and disorders associated to COVID-19. These results corroborated previous findings in COVID-19 studies and highlighted how the representation of dysregulated serum proteins and associated BPs increases with COVID-19 disease symptomatology from asymptomatic to severe cases. The analysis was then focused on novel disease processes and biomarkers that were correlated with disease symptomatology. To contribute to translational medicine, results corroborated the predictive value of selected immune-related biomarkers for disease recovery [Selenoprotein P (SELENOP) and Serum paraoxonase/arylesterase 1 (PON1)], severity [Carboxypeptidase B2 (CBP2)], and symptomatology [Pregnancy zone protein (PZP)] using protein-specific ELISA tests. Our results contributed to the characterization of SARS-CoV-2-host molecular interactions with potential contributions to the monitoring and control of this pandemic by using immune-related biomarkers associated with disease symptomatology.
000152040 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000152040 590__ $$a8.787$$b2021
000152040 591__ $$aIMMUNOLOGY$$b35 / 162 = 0.216$$c2021$$dQ1$$eT1
000152040 592__ $$a2.331$$b2021
000152040 593__ $$aImmunology and Allergy$$c2021$$dQ1
000152040 593__ $$aImmunology$$c2021$$dQ1
000152040 594__ $$a9.8$$b2021
000152040 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000152040 700__ $$aUrra, J.M.
000152040 700__ $$aRodriguez-del-Rio, F.J.
000152040 700__ $$aArtigas-Jeronimo, S.
000152040 700__ $$aJimenez-Collados, N.
000152040 700__ $$aFerreras-Colino, E.
000152040 700__ $$aContreras, M.
000152040 700__ $$aFernández de Mera, I.G. Estrada-Pena, A.
000152040 700__ $$0(orcid)0000-0001-7483-046X$$aGortazar, C.$$uUniversidad de Zaragoza
000152040 700__ $$ade la Fuente, J.
000152040 7102_ $$11009$$2773$$aUniversidad de Zaragoza$$bDpto. Patología Animal$$cÁrea Sanidad Animal
000152040 773__ $$g12 (2021), [18 pp.]$$pFront. immunol.$$tFrontiers in Immunology$$x1664-3224
000152040 8564_ $$s18440413$$uhttps://zaguan.unizar.es/record/152040/files/texto_completo.pdf$$yVersión publicada
000152040 8564_ $$s2568593$$uhttps://zaguan.unizar.es/record/152040/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000152040 909CO $$ooai:zaguan.unizar.es:152040$$particulos$$pdriver
000152040 951__ $$a2025-03-26-13:53:50
000152040 980__ $$aARTICLE